ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,686,241 | -17.1% | 320,837 | -4.7% | 0.01% | -18.8% |
| Q2 2023 | $8,065,736 | +31.9% | 336,774 | +3.7% | 0.02% | +33.3% |
| Q1 2023 | $6,112,922 | +62.2% | 324,810 | +37.2% | 0.01% | +50.0% |
| Q4 2022 | $3,769,329 | +21.7% | 236,767 | +24.9% | 0.01% | +14.3% |
| Q3 2022 | $3,098,000 | +300.3% | 189,497 | +244.4% | 0.01% | +250.0% |
| Q2 2022 | $774,000 | -75.4% | 55,029 | -57.7% | 0.00% | -60.0% |
| Q1 2022 | $3,149,000 | -2.8% | 130,105 | -6.4% | 0.01% | 0.0% |
| Q4 2021 | $3,241,000 | +52.9% | 138,950 | +8.7% | 0.01% | +25.0% |
| Q3 2021 | $2,120,000 | +497.2% | 127,778 | +775.3% | 0.00% | +300.0% |
| Q2 2021 | $355,000 | -49.6% | 14,599 | -46.8% | 0.00% | 0.0% |
| Q1 2021 | $705,000 | -45.9% | 27,424 | +12.6% | 0.00% | -66.7% |
| Q4 2020 | $1,302,000 | +178.8% | 24,362 | +114.9% | 0.00% | +200.0% |
| Q3 2020 | $467,000 | -82.1% | 11,339 | -79.0% | 0.00% | -83.3% |
| Q2 2020 | $2,613,000 | -52.7% | 54,005 | -58.8% | 0.01% | -57.1% |
| Q1 2020 | $5,527,000 | +53.1% | 130,943 | +55.1% | 0.01% | +100.0% |
| Q4 2019 | $3,611,000 | +24.9% | 84,415 | +5.1% | 0.01% | +16.7% |
| Q3 2019 | $2,891,000 | +19.1% | 80,288 | -11.6% | 0.01% | +20.0% |
| Q2 2019 | $2,428,000 | -4.0% | 90,838 | -3.6% | 0.01% | 0.0% |
| Q1 2019 | $2,529,000 | +1719.4% | 94,239 | +1000.7% | 0.01% | – |
| Q4 2018 | $139,000 | -21.9% | 8,562 | 0.0% | 0.00% | – |
| Q3 2018 | $178,000 | +169.7% | 8,562 | +96.4% | 0.00% | – |
| Q2 2018 | $66,000 | -53.5% | 4,360 | -31.0% | 0.00% | – |
| Q1 2018 | $142,000 | -29.4% | 6,317 | -2.2% | 0.00% | – |
| Q4 2017 | $201,000 | -58.8% | 6,458 | -50.2% | 0.00% | -100.0% |
| Q3 2017 | $488,000 | +53.0% | 12,959 | +13.1% | 0.00% | 0.0% |
| Q2 2017 | $319,000 | -61.6% | 11,459 | -52.6% | 0.00% | -50.0% |
| Q1 2017 | $831,000 | +473.1% | 24,150 | +379.7% | 0.00% | – |
| Q4 2016 | $145,000 | – | 5,034 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |